CV Sciences (CVSI) Cash & Current Investments (2011 - 2026)
CV Sciences (CVSI) reported Cash & Current Investments of $309000.0 for Q1 2026, down 61.95% on a YoY basis from $812000.0 in Q1 2025, and up 11.15% sequentially from $278000.0 in Q4 2025.
CV Sciences (CVSI) Cash & Current Investments (2011 - 2026) Analysis & Trends
CV Sciences (CVSI) has 16 years of Cash & Current Investments data on file, last reported at $309000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments fell 61.95% year-over-year to $309000.0; the trailing twelve-month figure through Mar 2026 stood at $309000.0 (down 61.95% YoY), and the FY2025 full-year result was $278000.0, down 38.77% from the prior year.
- Cash & Current Investments improved to $309000.0 in Q1 2026, from $278000.0 in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $2.4 million in Q1 2022 to a low of $278000.0 in Q4 2025.
- A 5-year average of $935588.2 and a median of $812000.0 in 2025 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments soared 115.55% in 2023 and tumbled 71.78% in 2024, its largest moves.
- Tracing CVSI's Cash & Current Investments over 5 years: stood at $611000.0 in 2022, then soared by 115.55% to $1.3 million in 2023, then sank by 65.53% to $454000.0 in 2024, then slumped by 38.77% to $278000.0 in 2025, then grew by 11.15% to $309000.0 in 2026.
- Business Quant data shows CVSI's Cash & Current Investments at $309000.0 in Q1 2026, $278000.0 in Q4 2025, and $381000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 428.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 309,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 309,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 381,000.00 |
| Jun 30, 2025 | 886,000.00 |
| Mar 31, 2025 | 812,000.00 |
| Dec 31, 2024 | 454,000.00 |
| Sep 30, 2024 | 979,000.00 |
| Jun 30, 2024 | 477,000.00 |
| Mar 31, 2024 | 662,000.00 |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 714,000.00 |
| Dec 31, 2022 | 611,000.00 |
| Sep 30, 2022 | 1.14 Mn |
| Jun 30, 2022 | 1.11 Mn |
| Mar 31, 2022 | 2.44 Mn |
| Dec 31, 2021 | 1.38 Mn |
| Jun 30, 2021 | 2.96 Mn |
| Mar 31, 2021 | 5.67 Mn |